论文部分内容阅读
目的以分组对比的形式,探讨性分析就甲状腺功能亢进应用他巴唑与131I治疗的临床作用。方法将抽取出于2011年2月~2013年2月间就本院就诊的80例甲状腺功能亢进患者作为本次研究对象。依据不同的治疗方法进行分组为他巴唑治疗组与131I治疗组,每组患者均为40例。观察并记录两组患者分别应用他巴唑与131I治疗后的临床疗效。结果应用131I治疗甲状腺功能亢进的疗效较他巴唑好,且复发率低。其中,他巴唑治疗组患者的基本治愈率、显效率分别为17.5%、35%;131I治疗组患者的基本治愈率、显效率分别为35%、45%。结论采取131I治疗甲状腺功能亢进具有安全性、有效性、复发率低等特点,适宜在临床上推广应用。
Objective To explore the clinical role of methimazole and 131I in the treatment of hyperthyroidism in the form of group comparison. Methods Eighty patients with hyperthyroidism from our hospital from February 2011 to February 2013 were selected as the study subjects. According to different treatment groups were divided into methimazole treatment group and 131I treatment group, each group of patients were 40 cases. Observed and recorded two groups of patients were treated with methimazole and 131I after the clinical efficacy. Results The application of 131I in the treatment of hyperthyroidism is better than that of terbazol, and the recurrence rate is low. The basic cure rate and effective rate of methimazole treatment group were 17.5% and 35% respectively. The basic cure rate and effective rate of 131I treatment group were 35% and 45% respectively. Conclusion 131I treatment of hyperthyroidism is safe, effective, low recurrence rate, suitable for clinical application.